Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers-Reference-Cited by-同舟云学术

Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers

Published:2016-02 Issue: Volume:43 Page:1-7
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Musolino Antonino,Boggiani Daniela,Sikokis Angelica,Rimanti Anita,Pellegrino Benedetta,Vattiato Rosa,Sgargi Paolo,Falcini Fabio,Caminiti Caterina,Michiara Maria,Leonardi Francesco

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Reference68 articles.

1. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement;U.S. Preventive Services Task Force;Ann Intern Med,2009

2. Integrating self-referral for mammography into organised screening: results from an Italian experience;Bucchi;J Med Screen,2003

3. Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study;Gori;BMC Cancer,2012

4. Endocrine sensitivity is decisive for patient outcome in small node negative breast cancers (BC) (pT1a, b) - results from the Munich Cancer Registry;Kolben;Breast,2015

5. Late mortality from pT1N0M0 breast carcinoma;Joensuu;Cancer,1999

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple metastases of human epidermal growth factor receptor 2‑positive, hormone receptor‑positive, pT1a pN0 breast cancer within 1 year after surgery: A case report;Oncology Letters;2024-06-12

2. A High Immune-Related Index with the Suppression of cGAS-STING Pathway is a Key Determinant to Herceptin Resistance in HER2+ Breast Cancer;International Journal of Biological Sciences;2024

3. Female breast cancer subtypes in the Romagna Unit of the Emilia-Romagna cancer registry, and estimated incident cases by subtypes and age in Italy in 2020;Journal of Cancer Research and Clinical Oncology;2023-03-15

4. Relationship between the changes of positivity rate of HER2 expression and the diameter of invasive lesions in early breast cancer and its clinical significance;Pathology - Research and Practice;2022-05

5. Clinicopathologic features of unexpectedly HER2 positive breast carcinomas: An institutional experience;Pathology - Research and Practice;2021-06